SkinBioTherapeutics Plc announced that following a successful handover, Stuart Ashman and Dr. Cath O'Neill will, with immediate effect, transition to the roles of Chief Executive Officer and Chief Scientific Officer respectively. Dr. O'Neill's primary focus will be on the scientific development of the Company, whilst Mr. Ashman looks to the future strategic direction of the Company and extended commercial opportunities. In addition, the Board is to establish a Scientific Advisory Board (SAB), of which Dr. O'Neill will be a member.

The SAB will be chaired by Dr. Cathy Prescott, a Non-Executive Director of the Company. In conjunction with the transition to the CSO role and as a member of the SAB, Dr. O'Neill is stepping down from the Board of the Company with immediate effect. Given the continuing positive progress of the Company and his increasing commitments at OptiBiotix Health Plc, Stephen O'Hara is stepping down from his position as Non-Executive Director of the company.